More stories

  • in

    Federal Reserve says 23 biggest banks weathered severe recession scenario in stress test

    All 23 of the U.S. banks included in the Federal Reserve’s annual stress test weathered a severe recession scenario while continuing to lend to consumers and corporations.
    The rate of total loan losses varied considerably across the banks, from a low of 1.3% at Charles Schwab to 14.7% at Capital One; credit cards were easily the most problematic loan product.
    Banks including JPMorgan Chase and Wells Fargo are expected to disclose updated plans for buybacks and dividends Friday after the close of regular trading.

    Michael Barr, Vice Chair for Supervision at the Federal Reserve, testifies about recent bank failures during a US Senate Committee on Banking, House and Urban Affairs hearing on Capitol Hill in Washington, DC, May 18, 2023.
    Saul Loeb | AFP | Getty Images

    All 23 of the U.S. banks included in the Federal Reserve’s annual stress test weathered a severe recession scenario while continuing to lend to consumers and corporations, the regulator said Wednesday.
    The banks were able to maintain minimum capital levels, despite $541 billion in projected losses for the group, while continuing to provide credit to the economy in the hypothetical recession, the Fed said in a release.

    Begun in the aftermath of the 2008 financial crisis, which was caused in part by irresponsible banks, the Fed’s annual stress test dictates how much capital the industry can return to shareholders via buybacks and dividends. In this year’s exam, the banks underwent a “severe global recession” with unemployment surging to 10%, a 40% decline in commercial real estate values and a 38% drop in housing prices.
    Banks are the focus of heightened scrutiny in the weeks following the collapse of three midsized banks earlier this year. But smaller banks avoid the Fed’s test entirely. The test examines giants including JPMorgan Chase and Wells Fargo, international banks with large U.S. operations, and the biggest regional players including PNC and Truist.
    As a result, clearing the stress test hurdle isn’t the “all clear” signal its been in previous years. Still expected in coming months are increased regulations on regional banks because of the recent failures, as well as tighter international standards likely to boost capital requirements for the country’s largest banks.  
    “Today’s results confirm that the banking system remains strong and resilient,” Michael Barr, vice chair for supervision at the Fed, said in the release. “At the same time, this stress test is only one way to measure that strength. We should remain humble about how risks can arise and continue our work to ensure that banks are resilient to a range of economic scenarios, market shocks, and other stresses.”

    Goldman’s credit card losses

    Losses on loans made up 78% of the $541 billion in projected losses, with most of the rest coming from trading losses at Wall Street firms, the Fed said. The rate of total loan losses varied considerably across the banks, from a low of 1.3% at Charles Schwab to 14.7% at Capital One.

    Credit cards were easily the most problematic loan product in the exam. The average loss rate for cards in the group was 17.4%; the next-worst average loss rate was for commercial real estate loans at 8.8%.
    Among card lenders, Goldman Sachs’ portfolio posted a nearly 25% loss rate in the hypothetical downturn — the highest for any single loan category across the 23 banks— followed by Capital One’s 22% rate. Mounting losses in Goldman’s consumer division in recent years, driven by provisioning for credit-card loans, forced CEO David Solomon to pivot away from his retail banking strategy.

    Regional banks pinched?

    The group saw their total capital levels drop from 12.4% to 10.1% during the hypothetical recession. But that average obscured larger hits to capital — which provides a cushion for loan losses — seen at banks that have greater exposure to commercial real estate and credit-card loans.
    Regional banks including U.S. Bank, Truist, Citizens, M&T and card-centric Capital One had the lowest stressed capital levels in the exam, hovering between 6% and 8%. While still above current standards, those relatively low levels could be a factor if coming regulation forces the industry to hold higher levels of capital.
    Big banks generally performed better than regional and card-centric firms, Jefferies analyst Ken Usdin wrote Wednesday in a research note. Capital One, Citigroup, Citizens and Truist could see the biggest increases in required capital buffers after the exam, he wrote.
    Banks are expected to disclose updated plans for buybacks and dividends Friday after the close of regular trading. Given uncertainties about upcoming regulation and the risks of an actual recession arriving in the next year, analysts have said banks are likely to be relatively conservative with their capital plans. More

  • in

    Overstock.com will change website name to Bed Bath & Beyond as deal closes

    Overstock.com will no longer go by its eponymous name online and will instead move under the Bed Bath & Beyond domain name in the coming weeks.
    The news comes after Overstock completed its $21.5 million acquisition of Bed Bath’s intellectual property and digital assets, which it hopes will lift sagging sales.

    A United Parcel Service worker loads orders onto a truck in the shipping area at the Overstock.com distribution center in Salt Lake City, Utah.
    Ken James | Bloomberg | Getty Images

    Overstock.com is going all in on failed retailer Bed Bath & Beyond.
    The e-commerce home goods retailer will no longer go by its eponymous name online and will instead move under the Bed Bath & Beyond domain name in the coming weeks after acquiring the bankrupt rival’s intellectual property, Overstock announced Wednesday.

    It will relaunch the Bed Bath & Beyond website in Canada within the next week, followed by a rollout of a website, mobile app and loyalty program in the U.S. “weeks later.”
    Overstock announced the moves as it completed its $21.5 million acquisition of Bed Bath’s intellectual property and digital assets. The company hopes the brand name will help to lift sagging sales.
    “Bed Bath & Beyond is an iconic consumer brand, well-known in the home retail marketplace,” Overstock CEO Jonathan Johnson said in a statement. “The combination of our winning asset-light business model and the high awareness and loyalty of the Bed Bath & Beyond brand will improve the customer experience and position the Company for accelerated market share growth.”
    Despite declining sales, Overstock’s stock has surged nearly 32% this year. Overstock shares jumped nearly 5% in extended trading Wednesday and also popped when it was first revealed that it successfully won the auction for Bed Bath’s assets.
    In its first-quarter results in April, Overstock reported $381 million in revenue, a 29% drop from the prior-year period. The e-commerce retailer posted a net loss of $10 million. Still, the retailer’s results came in ahead of some estimates, according to Street Account.

    Overstock will not acquire any brick-and-mortar Bed Bath stores as part of the deal. The failed home goods retailer has been hosting a series of auctions for its myriad assets, including its store leases and assets from its Buy Buy Baby banner.
    A number of bidders have expressed interest in Buy Buy Baby’s stores but it remains unclear if any will be bought and kept open. More

  • in

    Stocks making the biggest moves midday: Pinterest, Carnival, General Mills, Netflix and more

    A banner for the online image board Pinterest Inc. hangs from the New York Stock Exchange on the morning Pinterest made its initial public offering, April 18, 2019.
    Spencer Platt | Getty Images News | Getty Images

    Check out the companies making the biggest moves midday.
    Pinterest — Shares climbed 6.59%. Wells Fargo upgraded Pinterest to overweight due to an Amazon partnership expected to take hold later this year and optimism that Pinterest can continue to boost user engagement.

    Cruise stocks — Carnival popped 8.81%, Norwegian Cruise Line gained 7.55% and Royal Caribbean added 1.68%, extending gains from Tuesday after Carnival reported a smaller-than-expected loss for its second quarter and issued strong guidance. The sector has been on a tear this year as it recovers from the Covid-19 pandemic.
    General Mills — Shares tumbled 5.17% after the maker of Betty Crocker mixes and Cheerios cereal turned in a mixed earnings report for its fiscal fourth quarter. The company exceeded Wall Street expectations on earnings, posting $1.12 in adjusted earnings per share against a consensus estimate of $1.07 from analysts polled by Refinitiv. But $5.03 billion in revenue missed analysts’ forecast of $5.17 billion.
    Chip stocks — Shares of Nvidia slipped 1.81% and Advanced Micro Devices was down 0.2%, paring earlier losses, following a Wall Street Journal report that the U.S. is weighing new restrictions on artificial intelligence chip stocks sold to China.
    Netflix — The streaming giant jumped 3.06% after Oppenheimer raised its price target to $500 per share from $450. The Wall Street firm said it anticipated more subscribers and the potential discontinuation of its lowest-priced, ad-free plan, which is being tested in Canada.
    Joby Aviation — Shares soared 40.22% after the company announced it received a permit to begin flight testing its first electric vertical takeoff and landing vehicle (eVTOL).

    AeroVironment — Shares added 4.86% after the military drone maker reported revenue of $186 million after the market close Tuesday, topping analysts’ projection of $164 million, according to consensus estimates from Refinitiv. AeroVironment also said it anticipates full-year revenue of $630 million to $660 million, beating the $600 million expected by analysts.
    ZoomInfo — The software stock rose 6.09% after Needham initiated coverage of ZoomInfo with a buy rating. Needham said in a note to clients that ZoomInfo has “best in class unit economics.” ZoomInfo also received positive coverage from Morgan Stanley, which reiterated an overweight rating on the stock.
    Snowflake — Shares added 3.86% after the data cloud company reiterated its full-year guidance during an investor day Tuesday. Goldman Sachs reiterated its buy rating on Snowflake after the event and Morgan Stanley maintained an overweight recommendation.
    Circor International — The maker of flow control products for industrial and aerospace and defense markets users rallied 4.25% following a Reuters report that private equity firm Arcline has offered $57 per share, topping a rival bid from KKR.
    First Citizens BancShares — The regional bank gained 0.4%. Atlantic Equities initiated coverage of the North Carolina bank Wednesday with an overweight rating and $1,775 per share price target, which suggests nearly 50% upside from Tuesday’s close.
    — CNBC’s Alex Harring, Brian Evans, Jesse Pound and Michael Bloom contributed reporting. More

  • in

    Doubt grows over Buy Buy Baby sale process as parent Bed Bath & Beyond splits auction

    Bed Bath & Beyond will host two separate auctions for its Buy Buy Baby chain.
    The move, considered unusual in the world of bankruptcy, allows Bed Bath & Beyond to boost bids for its Buy Buy Baby chain. 
    The baby goods retailer has long been considered the crown jewel of Bed Bath & Beyond’s assets but interested buyers have recently cooled on keeping its stores open because of high costs, CNBC previously reported.

    A customer carries a Buy Buy Baby shopping bag in New York, Aug. 25, 2022.
    Gabby Jones | Bloomberg | Getty Images

    Bed Bath & Beyond is splitting the bankruptcy-run auction of its Buy Buy Baby chain into two phases as the retailer struggles to nail down bids in a sale process now shrouded in doubt.
    An auction for all of Buy Buy Baby’s assets was originally scheduled for 10 a.m. ET Wednesday. Now, only bids for the chain’s intellectual property, including its trademark and domain, will be accepted, according to people familiar with the matter.

    The failed home goods retailer is planning to host a separate auction, potentially Thursday, where buyers can submit bids to keep Buy Buy Baby and its stores running, said the people, who weren’t authorized to speak publicly on the matter.
    An initial winner will likely be chosen during Wednesday’s intellectual property auction. That bidder and other suitors can participate in the second auction. If Bed Bath & Beyond receives a higher offer for the entire banner than it gets for the intellectual property, that bidder could be selected and supersede the winner of Wednesday’s auction, the people said. 
    The decision to split up the bidding comes after the retailer held separate sale proceedings for its Buy Buy Baby and Bed Bath & Beyond banners. 
    The move, considered unusual in the world of bankruptcy, allows Bed Bath & Beyond to boost bids for its Buy Buy Baby chain as doubts grow about what, if any, offers will come in, some of the people said.
    The banner, which sells baby goods such as strollers, clothes and cribs, has long been considered the crown jewel of Bed Bath & Beyond’s assets. It attracted interest from numerous bidders both before and after its parent company declared bankruptcy. Some prospective buyers considered keeping stores open. 

    But as the auction drew nearer, interest in keeping those stores alive waned and the retailer has struggled to nail down bids in an increasingly uncertain sale process, some of the people said.

    A Buy Buy Baby retail store in New York, Aug. 25, 2022.
    Gabby Jones | Bloomberg | Getty Images

    Bidders interested in purchasing Buy Buy Baby and operating its brick-and-mortar stores and online presence would need to purchase the bulk of its 100-plus locations to reach profitability. 
    The expenses behind running the stores, such as leases, overhead costs and salaries, make it difficult to reach profitability if a buyer acquires only a fraction of Buy Buy Baby’s doors along with its intellectual property. 
    “There’s not a profitable model where you only have 10 stores or 40 stores,” a person with knowledge of the matter previously told CNBC. 
    Bed Bath & Beyond did not respond to CNBC’s request for comment.
    A credit bid from pre-bankruptcy lender Sixth Street Partners, which could team up with an e-commerce platform, is considered a top contender, some of the people said. It’s unclear if the offer will go beyond the intellectual property assets. Sixth Street Partners did not respond to CNBC’s request for comment.
    Go Global Retail — which owns the children’s wear brand Janie and Jack — was initially interested in keeping Buy Buy Baby stores open, but the number of locations it was interested in saving has since dwindled to about 20 stores, if any at all, CNBC previously reported. 
    Direct-to-consumer online registry Babylist has submitted a bid to acquire some of Buy Buy Baby’s assets, such as its domain name and trademark, but opted out of bidding for its stores, CEO Natalie Gordon previously told CNBC.
    Earlier this month, Overstock.com won the auction for Bed Bath & Beyond’s assets and purchased the banner’s intellectual property and digital assets for $21.5 million. The digital retailer didn’t agree to purchase any of Bed Bath & Beyond’s stores.  More

  • in

    Zaslav brings in Spielberg, Scorsese, Anderson to help curate TCM film lineup after shakeup

    Warner Bros. Discovery is bringing in top filmmakers including Steven Spielberg and Martin Scorsese to provide input on film curation at cable-TV network TCM.
    The agreement came after CEO David Zaslav’s discussion with the filmmakers following a shakeup at the classic film channel.
    Warner Bros. Discovery said its investment in TCM has grown by 30%, and the company plans to build on that in the future.

    Steven Spielberg attends the 55th Annual Cinema Audio Society Awards at InterContinental Los Angeles Downtown on February 16, 2019 in Los Angeles, California.
    Matt Winkelmeyer | Getty Images Entertainment | Getty Images

    Warner Bros. Discovery is calling in a filmmaker brain trust to help steer the curation and programming of its cable-TV channel Turner Classic Movies, after a shakeup among management left fans concerned about the network’s future.
    “Jaws” director Steven Spielberg, “Goodfellas” helmer Martin Scorsese and “Boogie Nights” filmmaker Paul Thomas Anderson officially signed on to provide their input at TCM, the company and filmmakers said on Wednesday. The filmmakers will work closely with Warner Bros. Motion Picture Group chiefs Mike De Luca and Pam Abdy, who are overseeing curation and programming after a series of layoffs and management shakeup at TCM, according to the company.

    “We have already begun working on ideas with Mike and Pam, both true film enthusiasts who share a passion and reverence for classic cinema that is the hallmark of the TCM community,” the three filmmakers said in a joint statement on Wednesday. “This unique arrangement, initiated by David Zaslav, reflects his commitment to honoring the TCM legacy while also involving us on curation and programming.”
    The inclusion of the filmmakers came after Warner Bros. Discovery employees last week faced another round of layoffs, particularly across its portfolio of cable-TV networks.
    Part of that was a major shakeup at TCM, recognized as a place for preservation of classic films and a carefully curated lineup augmented by guest star introductions. The changes had caused concern among movie buffs and those dedicated to film preservation, who voiced their distress on social media.
    The filmmakers also applauded that longtime programming chief Charles Tabesh, who was initially set to leave as part of the shakeup, will stay with the network.

    David Zaslav, CEO, Warner Bros. Discovery.
    Anjali Sundaram | CNBC

    Last week, the filmmakers had said in a statement Zaslav contacted and reassured them, and they were committed to working with the company for TCM’s future.

    Since the 2022 merger between Warner Bros. and Discovery, the company has been undergoing a number of cost-cutting initiatives, including layoffs and cutting back on content spending.
    In the months leading up to the job cuts and changes at the networks, including TCM, Zaslav and Spielberg held conversations about TCM’s future, according to a person familiar with the matter. Zaslav also initiated the conversation with Spielberg, Scorsese and Anderson last week.
    Spielberg and Anderson and joined Zaslav on a panel during the TCM Classic Film Festival in April about film preservation efforts, according to media reports.
    Warner Bros. Discovery and its film chiefs touted the company’s increased investment in TCM recently.
    “TCM is a cultural treasure which WBD is fully committed to safeguarding, supporting, and investing in for the future. This year, TCM’s content investment has grown by 30% and we plan to build on that in future years,” a company spokesperson said in a statement. “That said, TCM is not immune to the very real pressure on the entire linear ecosystem, but we have taken steps to ensure that we stay true to the mission of the network – bringing more titles to the air, driving content investment, and preserving and protecting the culture of cinema.”
    The increased investment will go toward licensing new films and bringing a wider roster to the network, according to the person familiar with the matter. More

  • in

    The working-from-home delusion fades

    A gradual reverse migration is under way, from Zoom to the conference room. Wall Street firms have been among the most forceful in summoning workers to their offices, but in recent months even many tech titans—Apple, Google, Meta and more—have demanded staff show up to the office at least three days a week. For work-from-home believers, it looks like the revenge of corporate curmudgeons. Didn’t a spate of studies during the covid-19 pandemic demonstrate that remote work was often more productive than toiling in the office? Unfortunately for the believers, new research mostly runs counter to this, showing that offices, for all their flaws, remain essential. A good starting point is a working paper that received much attention when it was published in 2020 by Natalia Emanuel and Emma Harrington, then both doctoral students at Harvard University. They found an 8% increase in the number of calls handled per hour by employees of an online retailer that had shifted from offices to homes. Far less noticed was a revised version of their paper, published in May by the Federal Reserve Bank of New York. The boost to efficiency had instead become a 4% decline.The researchers had not made a mistake. Rather, they received more precise data, including detailed work schedules. Not only did employees answer fewer calls when remote, the quality of their interactions suffered. They put customers on hold for longer. More also phoned back, an indication of unresolved problems.The revision comes hot on the tails of other studies that have reached similar conclusions. David Atkin and Antoinette Schoar, both of the Massachusetts Institute of Technology, and Sumit Shinde of the University of California, Los Angeles, randomly assigned data-entry workers in India to labour either from home or the office. Those working at home were 18% less productive than their peers in the office. Michael Gibbs of the University of Chicago and Friederike Mengel and Christoph Siemroth, both of the University of Essex, found a productivity shortfall, relative to prior in-office performance, of as much as 19% for the remote employees of a large Asian it firm. Another study determined that even chess professionals play less well in online matches than face-to-face tilts. Yet another used a laboratory experiment to show that video conferences inhibit creative thinking.The reasons for the findings will probably not surprise anyone who has spent much of the past few years working from a dining-room table. It is harder for people to collaborate from home. Workers in the Fed study spoke of missing their “neighbours to turn to for assistance”. Other researchers who looked at the communication records of nearly 62,000 employees at Microsoft observed that professional networks within the company become more static and isolated. Teleconferencing is a pale imitation of in-the-flesh meetings: researchers at Harvard Business School, for example, concluded that “virtual water coolers”—rolled out by many companies during the pandemic—often encroached on crowded schedules with limited benefits. To use the terminology of Ronald Coase, an economist who focused on the structure of companies, all these problems represent an increase in co-ordination costs, making collective enterprise more unwieldy.Some of the co-ordination costs of remote work might reasonably be expected to fall as people get used to it. Since 2020, many will have become adept at using Zoom, Webex, Teams or Slack. But another cost may rise over time: the underdevelopment of human capital. In a study of software engineers published in April, Drs Emanuel and Harrington, along with Amanda Pallais, also of Harvard, found that feedback exchanged between colleagues dropped sharply after the move to remote work. Drs Atkin, Schoar and Shinde documented a relative decline in learning for workers at home. Those in offices picked up skills more quickly.The origins of the view that, contrary to the above, remote working boosts productivity can be traced to an experiment nearly a decade before the pandemic, which was reported by Nicholas Bloom of Stanford and others in 2013. Call-centre workers for a Chinese online travel agency now known as Trip.com increased their performance by 13% when remote—a figure that continues to appear in media coverage today. But two big wrinkles are often neglected: first, more than two-thirds of the improved performance came from employees working longer hours, not more efficiently; second, the Chinese firm eventually halted remote work because off-site employees struggled to get promoted. In 2022 Dr Bloom revisited Trip.com, this time to investigate the effects of a hybrid-working trial. The outcomes of this experiment were less striking: it had a negligible impact on productivity, though workers put in longer days and wrote more code when in the office.The price of happinessThere is more to work (and life) than productivity. Perhaps the greatest virtue of remote work is that it leads to happier employees. People spend less time commuting, which from their vantage-point might feel like an increase in productivity, even if conventional measures fail to detect it. They can more easily fit in school pick-ups and doctor appointments, not to mention the occasional lie-in or mid-morning jog. And some tasks—notably, those requiring unbroken concentration for long periods—can often be done more smoothly from home than in open-plan offices. All this explains why so many workers have become so office-shy.Indeed, multiple surveys have found employees are willing to accept pay cuts for the option of working from home. Having satisfied employees on slightly lower pay, in turn, might be a good deal for corporate managers. For many people, then, the future of work will remain hybrid. Nevertheless, the balance of the work week is likely to tilt back to the office and away from home—not because bosses are sadomasochists with a kink for rush-hour traffic, but because better productivity lies in that direction. ■ More

  • in

    As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge

    Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry.
    For now, one experimental oral drug from Eli Lilly appears to have an edge over pills from Novo Nordisk and Pfizer — even though it may not win U.S. approval first. 
    Eli Lilly’s orforglipron appears to be the top contender due to its strong efficacy data and convenience as a once-daily pill without dietary restrictions. 
    But pivotal data from several pharmaceutical companies is slated to come out later this year and pricing of all the major drugs is still uncertain.

    Daniel Acker | Bloomberg | Getty Images

    Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry: effective, convenient and potentially affordable obesity pills. 
    An estimated 40% of U.S. adults are obese, making a successful pill a massive opportunity.

    It’s too early to crown a winner, especially since pivotal data from several pharmaceutical companies is slated to come out later this year. And there’s still the all-important issue of pricing for the major players.
    But for now, one experimental oral drug from Eli Lilly appears to have an edge over pills from Novo Nordisk and Pfizer — even though it may not win U.S. approval first. 
    All three manufacturers are developing oral versions of GLP-1s, a class of drug that mimics a hormone produced in the gut to suppress a person’s appetite. Novo Nordisk’s popular Wegovy and Ozempic treatments, which sparked a weight loss industry gold rush last year, are weekly GLP-1 injections also known as semaglutide.
    The pills are easier to manufacture than injections, which come in the form of single-use pens. That means the oral drugs could potentially help alleviate the supply shortages plaguing their injectable counterparts. 
    Pills are also typically cheaper than injections, though it’s unclear if that will be the case with the obesity pills. 

    Wegovy’s list price tops $1,300 per monthly package, and Ozempic’s is about $935. Novo Nordisk has a low-dose oral version of semaglutide that has the same list price as Ozempic for a monthly package of 30 tablets. That pill, marketed as Rybelsus, is approved only for Type 2 diabetes.
    None of the three drugmakers has provided estimates for how much the new obesity pills would cost. 
    Novo Nordisk has one important advantage: The Danish company has already released phase three clinical trial results for its high-dose version of oral semaglutide, which is intended for weight management, and told CNBC it expects to file for Food and Drug Administration approval later this year.
    Eli Lilly is still in the middle of phase three clinical trials on its oral drug, orforglipron, meaning it’s likely to hit the market later.
    Still, analysts are confident in the competitive edge of orforglipron in the long run, especially after Eli Lilly unveiled phase two clinical trial results last week that showcased the drug’s strong efficacy profile.  

    Strong efficacy profile

    According to Eli Lilly’s phase two results, overweight or obese patients who took 45 milligrams of orforglipron once a day lost up to 14.7% of their body weight after 36 weeks. That compares with a weight loss of 2.3% for people who received a placebo. 
    Eli Lilly’s results appear consistent with the weight reduction caused by Novo Nordisk’s pill, but were achieved over a shorter trial period.
    Overweight or obese patients who took 50 milligrams of Novo Nordisk’s drug once a day saw an average weight loss of 15.1% after 68 weeks, according to phase three clinical trial results released Sunday. 
    Bank of America analyst Geoff Meacham said in a Sunday research note that Eli Lilly’s available orforglipron data “compares quite favorably” to Novo Nordisk’s oral semaglutide, “cross trial comparison caveats aside.” 
    Cantor Fitzgerald analyst Louise Chen told CNBC that orforglipron could potentially achieve an even greater level of weight loss over a longer trial period. 
    “The more you use these drugs, the more weight loss you’ll see until it plateaus, right?” Chen said. “So the thought is, if you’re getting pretty close to semaglutide’s weight loss in almost roughly half the time with orforglipron, you will probably exceed it.” 
    Chen said the hope is that orforglipron leads to a reduction similar to that of Eli Lilly’s injection tirzepatide, which resulted in weight loss of around 22% after 72 weeks. 
    The company’s phase three clinical trials on orforglipron will study the drug over longer time periods. 
    At least for now, analysts say Eli Lilly’s pill may also have the upper hand over Pfizer’s oral GLP-1, danuglipron, which is still in phase two clinical trials.
    Patients with Type 2 diabetes who took a 120-milligram version of danuglipron twice a day lost around 10 pounds on average after 16 weeks, according to results from one phase two clinical trial.
    It’s difficult to compare danuglipron’s efficacy with that of other oral GLP-1s due to differing patient populations and the lack of longer-term data on the drug. 
    A Pfizer spokesperson told CNBC that the company is still studying the drug in further phase two clinical trials and “would also look to have longer data” beyond the 16-week mark in the future. 

    Ease of use

    Wells Fargo analyst Mohit Bansal said in a research note that Pfizer’s danuglipron will be challenged to compete in the oral GLP-1 space given Eli Lilly’s strong orforglipron data. 
    He added that physicians generally prefer once-daily pills — like orforglipron — over twice-daily drugs such as danuglipron. 
    Health experts seem to agree: “Patient compliance increases a lot if it’s a once-a-day pill, so it’s definitely a big advantage. People often end up missing a few times a week if they have to take something twice a day,” said Dr. John Yoon, an endocrinology professor at UC Davis Health. 
    Pfizer is developing a once-daily version of danuglipron.
    The company on Monday also said it would stop developing another experimental pill, lotiglipron, which Bansal said had been the “more attractive GLP-1” in Pfizer’s portfolio since it’s only taken once a day. Shares of Pfizer fell 5% on Monday following that news.
    But Pfizer and Eli Lilly do share one key advantage over Novo Nordisk’s oral semaglutide: no dietary restrictions. 
    Patients need to take Novo Nordisk’s oral semaglutide in the morning on an empty stomach with no more than four ounces of plain water, according to the FDA label for the low-dose, approved version of the drug. They’re instructed to wait 30 minutes before eating, drinking or taking other oral medicines.
    That’s because Novo Nordisk’s oral semaglutide is a peptide medication, which is more difficult for the gut to absorb, according to Dr. Eduardo Grunvald, medical director for UC San Diego’s Center for Advanced Weight Management.
    “If you take it with food or drink, it just won’t get absorbed efficiently,” Grunvald told CNBC.
    He said pills from Eli Lilly and Pfizer are non-peptide GLP-1s, which are absorbed more easily and don’t require dietary restrictions. 
    Cantor Fitzgerald’s Chen said market research suggests that those restrictions are a “big negative for patients,” making the pills from Eli Lilly and Pfizer convenient alternatives. 
    Overall, Eli Lilly’s orforglipron appears to be the top contender in the weight loss pill space due to its strong efficacy data and convenience as a once-daily pill without dietary restrictions. 
    But Chen emphasized that the data unveiled later this year could potentially change that: “Save some room for the new data coming.” 
    For health experts such as Grunvald, naming a winner in the oral weight loss drug space is less important.
    “I think these oral GLP-1s mean having more tools in our toolbox, having more options for different people who might react differently to different medicines,” he said. “That’s really the future of this all.” More

  • in

    How to escape China’s property crisis

    Getting into Jinjiang Ode is a little difficult. The luxurious property development in central Chengdu will not allow potential buyers through its four-metre-high palatial gates without an appointment. Even finding out about the project in the south-western metropolis, home to 16m people, is tricky. The firm behind it is so confident of demand that it does not deign to advertise the flats—a confidence which is not unjustified. Chengdu has a distinct, laid-back atmosphere epitomised by its public tea gardens, in which patrons spend hours sipping hot beverages and having their ears cleaned. The leisurely pace of life and tongue-numbing local cuisine appeal to younger Chinese people, who have come in droves in recent years, says Zhang Xiaojun, a sales agent at the development. Many of them buy homes.As a prolonged downturn in China’s property market takes hold, Chengdu seems to be an outlier. By several metrics, including house prices and sales of new homes, it is faring better than almost anywhere in the country. At a national level, the central government’s response to the deepening property crisis, including an interest-rate cut announced on June 13th, has underwhelmed. China’s benchmark stock index has fallen by 8% since its peak this year in early May, when the country still appeared to be rocketing towards a full post-covid recovery. Now investors fear more developers will start to fall short of cash, defaulting on dollar debts in the process. Experts are asking how much local measures can pump up growth. Chengdu is a good place to search for answers.There is a faint air of unreality about the local market. New home sales between April and June were 30% higher than in the same period in 2019, the last year before the covid-19 pandemic struck, notes Larry Hu of Macquarie, an investment bank. In contrast, across China’s 30 largest cities, sales have fallen by 25%. Meanwhile, in May home prices in Chengdu rose by 8% compared with the previous year, the most of any large city. It has notched month-on-month rises for 17 straight months. Many Chinese cities are working through vast inventories of flats that have been built but not sold: it will take the southern city of Zhuhai more than 12 years to sell homes that have been completed or are still under construction if sales stay at the current pace. Chengdu will sell such flats in just over three years.What explains the success? Since 2016 officials in every Chinese city have been able to devise their own measures for cooling or heating local property markets. Most of the rules employed are restrictions on who can buy a flat, how many they may purchase and the size of the downpayment required. In most large cities, only people with local hukou, or residence permits, are allowed to buy homes. In Chengdu, high-level purchase controls remain in place. But officials have sought to attract families as a way of expanding the city and increasing demand for homes. Residents with two or more children are, for instance, allowed to buy additional homes, and local hukou-holders may buy up to three. Even those without a hukou may buy two. Since the start of the year, elderly parents who move to Chengdu to join their adult children may also purchase a flat.Other cities have experimented with similar policies, but enjoyed much less success. Shenzhen, the technology hub across the border from Hong Kong, has relaxed some of its restrictions. Yet property prices are still down 1.8% year-on-year. One explanation for this is sweeping layoffs in the city’s tech sector. Another is that Chengdu’s policies are more effective because they are paired with reforms to attract educated workers, which have helped boost growth. Since 2017 local authorities have handed out housing subsidies and cash rewards to talented people who move to the city in order to work in its rapidly growing industrial base, points out Sandra Chow of CreditSights, a research firm.Chengdu’s officials also did a better job of tackling the crisis of confidence that spread across the country last year. As developers went bust, many failed to finish flats. Thousands of homebuyers responded by halting mortgage payments. Many more delayed buying new homes. Officials in Chengdu went to great lengths to ensure homes were handed over, funnelling cash to developers, says Ms Chow. Even defaulting developers managed to complete homes. About 40% more apartment space was finished in the first two months of 2023 compared with the same period the year before. This probably encouraged wavering buyers to take the plunge. Other regions may have wanted to follow suit, but lacked the cash. Sichuan, where Chengdu sits, notched up the strongest growth in municipal land sales of any province in the first half of 2022, which will have freed up funds to keep builders at work.Chengdu benefited from some other factors that will be difficult, if not impossible, to replicate elsewhere, and perhaps even in the city itself. Its population rose by more than 7m from 2011 to 2021, making it one of the fastest-growing urban areas anywhere in the world. These inflows have been the biggest driver for housing demand, says Yan Yuejin of E-House China, a research firm. But urban migration has since slowed. There are simply not enough people in China for another population boom. Chengdu’s location in the south-west also meant it did not see rapid rises in prices in past housing booms. Moreover, its growing manufacturing industry continued to lift incomes. As Louise Loo of Oxford Economics, another research firm, notes, it is thus one of just a few second-tier cities that have not seen rapid price increases relative to local incomes.A few levers remain for Chengdu’s officials should things start to look peaky. They have yet to drastically ease restrictions, allowing many more people to buy homes. Market-watchers are waiting for such a development, says Guo Jie of the Local Association of Real Estate Enterprises, an industry group, for it would indicate that steam is running out and that even the best-prepared cities are being swept into the crisis. Policymakers elsewhere in the country will be watching closely, too. ■ More